Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy

Pharmaceutical Research

Volumn 32, Issue 9, 2015, Pages 2837-2850

  Zhang, Weifeng ^a,b   Wang, Lianyan ^a   Yang, Tingyuan ^a   Liu, Yuan ^a,b   Chen, Xiaoming ^a,b   Liu, Qi ^a,b   Jia, Jilei ^a,b   Ma, Guanghui ^a,c  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Collaborative Innovation Center of Chemical Science and Engineering   (China)

Author keywords

adjuvant; imiquimod; immune response; microparticles; subunit vaccine

Indexed keywords

IMIQUIMOD; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 6; OVALBUMIN; POLYGLACTIN; POLYMER; SUBUNIT VACCINE; TUMOR NECROSIS FACTOR ALPHA; AMINOQUINOLINE DERIVATIVE; ANTIGEN; LACTIC ACID; PHARMACEUTICAL VEHICLES AND ADDITIVES; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EMULSION; FEMALE; IMMUNOPOTENTIATION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H5N1); MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1);

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; AMINOQUINOLINES; ANIMALS; ANTIGENS; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; OVALBUMIN; POLYGLYCOLIC ACID; POLYMERS; VACCINES;

EID: 84938738008     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1666-6     Document Type: Article

References (30)

1. Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharm Res. 2014;31(10):2563-82.
2. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol. 2006;24(11):1377-83.
3. Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, Fréchet JMJ. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc Natl Acad Sci U S A. 2009;106(14):5497-502.
4. Sokolova V, Knuschke T, Kovtun A, Buer J, Epple M, Westendorf AM. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials. 2010;31(21):5627-33.
5. Zhang W, Wang L, Liu Y, Chen X, Liu Q, Jia J, et al. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials. 2014;35(23):6086-97.
6. Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. Chem Med Chem. 2013;8(3):360-76.
7. Fischer NO, Rasley A, Blanchette C. Nanoparticles and antigen delivery: understanding the benefits and drawbacks of different delivery platforms. Nanomedicine. 2014;9(4):373-6.
8. Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2011;2(8):1057-77.
9. Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J Leukocyte Biol. 2006;80(5):1084-102.
10. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492-503.
11. Rizwan SB, McBurney WT, Young K, Hanley T, Boyd BJ, Rades T, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16-21.
12. Zhang W, Wang L, Liu Y, Chen X, Li J, Yang T, et al. Comparison of PLA microparticles and Alum as adjuvants for H5N1 influenza split vaccine: adjuvanticity evaluation and preliminary action mode analysis. Pharm Res. 2014;31(4):1015-31.
13. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157-64.
14. Bachelder EM, Beaudette TT, Broaders KE, Fréchet JMJ, Albrecht MT, Mateczun AJ, et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm. 2010;7(3):826-35.
15. Primard C, Poecheim J, Heuking S, Sublet E, Esmaeili F, Borchard G. Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization. Mol Pharm. 2013;10(8):2996-3004.
16. Paula DD, Martins CA, Bentley MVLB. Development and validation of HPLC method for imiquimod determination in skin penetration studies. Biomed Chromatogr. 2008;22(12):1416-23.
17. Bachute MT, Turwale SL. A rapid and validated reverse phase liquid chromatographic method for determination of imiquimod from topical cream formulations. J Pharm Res. 2013;6(1):73-7.
18. Liu Y, Yin Y, Wang L, Zhang W, Chen X, Yang X, et al. Surface hydrophobicity of microparticles modulates adjuvanticity. J Mater Chem B. 2013;1(32):3888-96.
19. Selvarajan K, Moldovan L, Chandrakala AN, Litvinov D, Parthasarathy S. Peritoneal macrophages are distinct from monocytes and adherent macrophages. Atherosclerosis. 2011;219(2):475-83.
20. Liu Y, Yin Y, Wang LY, Zhang WF, Chen XM, Yang XX, et al. Engineering biomaterial-associated complement activation to improve vaccine efficacy. Biomacromolecules. 2013;14(9):3321-8.
21. Murtaugh MP, Foss DL. Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunop. 2002;87(3-4):109-21.
22. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510-2.
23. Woof JM. Tipping the scales toward more effective antibodies. Science. 2005;310(5753):1442-3.
24. Stano A, Scott EA, Dane KY, Swartz MA, Hubbell JA. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Biomaterials. 2013;34(17):4339-46.
25. Marzio R, Mauël J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharm Immunot. 1999;21(3):565-82.
26. Lindsey W, Lowdell M, Marti G, Abbasi F, Zenger V, King K, et al. CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. Cytotherapy. 2007;9(2):123-32.
27. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30(33):4907-20.
28. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis. 2007;196(Supplement 2):S413-20.
29. Schotsaert M, Saelens X, Leroux-Roels G. Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines. 2012;11(8):949-62.
30. Ma Y, Zhuang Y, Xie X, Wang C, Wang F, Zhou D, et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale. 2011;3(5):2307-14.